Rezdiffra, a novel thyroid hormone receptor-beta (THR-β) agonist, emerges as a beacon of hope for adults grappling with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis (stages F2 to F3). The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.